


Financial tear sheet

Corporate Profile

2015 was a pivotal year for Baxter: In July we executed the spinoff of our BioScience business. The corporate separation created value for investors and resulted in a Baxter portfolio focused solely on the Hospital Products and Renal technologies central to our core identity. Today we are collaborating around the world to shape a leaner, more efficient company, positioned to deliver on our mission and succeed on behalf of all our stakeholders well into the future.

Stock Information

BAX (BAX)	
Exchange	NYSE (US Dollar)
Price	\$65.33
Change (%)	▲ 0.55 (0.85%)
Volume	4,988,937
52 Week Low	\$43.81
Market Cap	\$35,593,869,530
Rolling EPS	1.85
PE Ratio	34.9343
Shares Outstanding	544,831,923
Data as of 12/15/2017 4:00 PM ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

DATE	TITLE
12/11/17	Baxter to Present at the 36th Annual J.P. Morgan Healthcare Conference
12/06/17	Baxter International Foundation and Direct Relief Mobile Health Program Connects 23,000 People to Critical Health Services in First Year
12/04/17	Baxter to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

Recent & Upcoming Events

DATE	TITLE
10/25/2017 8:30 AM ET	Q3 2017 Baxter International Inc. Earnings Conference Call
11/07/2017 2:10 PM MT	26th Annual Credit Suisse Healthcare Conference Location Scottsdale, AZ
11/28/2017 7:30 AM ET	Piper Jaffray Healthcare Conference Location New York

SEC Filings

FILING DATE	FORM
12/06/17	4
11/17/17	4
11/07/17	4
11/02/17	10-Q

Primary IR Contact

Clare Trachtman
Baxter International Inc.
Phone: 224-948-3085